• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>Multiscale mechanobiology of bone remodeling and adaptation >Application of Disease System Analysis to Osteoporosis: From Temporal to Spatio-Temporal Assessment of Disease Progression and Intervention
【24h】

Application of Disease System Analysis to Osteoporosis: From Temporal to Spatio-Temporal Assessment of Disease Progression and Intervention

机译：疾病系统分析在骨质疏松症中的应用：从疾病进展和干预的时空评估到时空评估

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Osteoporosis (OP) is a progressive bone disorder regarded as an important worldwide health issue. OP is characterised by a slow reduction of the bone matrix and changes in the bone matrix properties. Novel drug treatments are continuously developed to reduce the risk of bone fractures. Assessing the effects of novel and existing treatments on OP can be challenging. This is due to the difficulties of establishing the effects of the drug on the disease progression as reflected in the slowly changing bone mineral density (BMD). In recent years, our understanding of the pathophysiology of OP has considerably improved. Biomarkers reflecting bone physiology have been identified at the cellular, tissue and organ levels. Cellular biomarkers reflect the dynamics of bone remodelling (i.e., bone formation and resorption) on a short time scale. On the other hand, tissue and organ scale biomarkers show changes of BMD and bone structural arrangements on a larger time scale. Biomarkers can be used to characterise bone remodelling and to quantify the effect of the drug on OP. Recently, the concept of disease system analysis (DSA) has been proposed as a novel approach to quantitatively characterise drug effects on disease progression. This approach integrates physiology, disease progression and drug treatment in a comprehensive mechanism-based modelling framework using a large amount of complementary biomarker data. This chapter will provide an overview of the use of DSA to characterise drug effects on OP. We will review classical (i.e., non-mechanistic) pharmacokinetic-pharmacodynamic (PK/PD) models used to study drug dose-effect responses. Latest mechanistic bone remodelling models will be presented together with the study of the effect of the drug denosumab on disease progression in postmenopausal osteoporosis (PMO). Finally, we will provide an outlook on how to extend the temporal mechanistic model towards a spatio-temporal description. We conclude that the development of fully mechanistic disease system models of OP has great potential to adequately predict the long-term effects of drug treatments on clinical outcomes. This may provide a means for patient-specific estimation of bone fracture risk.
机译：骨质疏松症（OP）是一种进行性骨病，被认为是全球重要的健康问题。 OP的特征在于骨基质的缓慢还原和骨基质性质的变化。不断开发新的药物治疗以降低骨折的风险。评估新型疗法和现有疗法对OP的影响可能具有挑战性。这是由于难以确定药物对疾病进展的作用，这反映在缓慢变化的骨矿物质密度（BMD）中。近年来，我们对OP的病理生理学的了解已大大提高。已经在细胞，组织和器官水平上鉴定出反映骨骼生理的生物标志物。细胞生物标记物可在短时间内反映出骨骼重塑的动态（即骨骼形成和吸收）。另一方面，组织和器官尺度的生物标志物在更长的时间尺度上显示出BMD和骨骼结构排列的变化。生物标志物可用于表征骨重塑并量化药物对OP的作用。最近，已经提出了疾病系统分析（DSA）的概念，作为定量表征药物对疾病进展的影响的新方法。这种方法使用大量的补充生物标记数据，将生理学，疾病进展和药物治疗整合在一个基于机制的综合建模框架中。本章将概述使用DSA表征药物对OP的作用。我们将回顾用于研究药物剂量效应反应的经典（即非机械）药代动力学-药效学（PK / PD）模型。最新的机械骨骼重塑模型将与药物地诺单抗对绝经后骨质疏松症（PMO）疾病进展的影响一起研究。最后，我们将提供关于如何将时态机制模型扩展到时空描述的观点。我们得出的结论是，OP的完全机械性疾病系统模型的开发具有很大的潜力，可以充分预测药物治疗对临床结果的长期影响。这可以提供用于患者特定的骨折风险估计的方法。

著录项

  • 来源
  • 会议地点
  • 作者

    Silvia Trichilo; Peter Pivonka;

  • 作者单位

    St Vincent's Department of Surgery, The University of Melbourne, Melbourne, VIC, Australia,Australian Institute of Musculoskeletal Science, Melbourne, VIC, Australia;

    St Vincent's Department of Surgery, The University of Melbourne, Melbourne, VIC, Australia,Australian Institute of Musculoskeletal Science, Melbourne, VIC, Australia,School of Chemistry, Physics and Mechanical Engineering, Queensland University of Technology, Brisbane, QLD, Australia;

  • 会议组织
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号